FDA Approves Lyrfigtu (lirafugratinib) for the Treatment of Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

Sep 25, 2026 - 00:00
 0  0
FORT LEE, N.J., September 23, 2026 – Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for cancer patients...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0